Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
J Med Virol ; 2022 Nov 04.
Article in English | MEDLINE | ID: covidwho-2246770


We appreciate the comments from Chan et al. for our study, and have carefully responded to the comments of Chan et al. and are very grateful for their praise of our research. We agree that smoking might be a risk factor of the severity of COVID-19 as mentioned by Chan et al., but in our study, smoking was not so robust compared with our conclusion. Also, we strongly agreed with the opinion of Chan, et al. that COVID-19 patients with diabetes or other chronic diseases might worsen the situation of the disease. But these factors were out of the scope of our study and we had published other research on this topic related to diabetes. Because of the limited sample size and original medical records, our study could not cover many factors suggested as Chan, et al. But we wish our study will be a useful and meaningful pilot study for the future studies. This article is protected by copyright. All rights reserved.

J Med Virol ; 94(10): 4727-4734, 2022 10.
Article in English | MEDLINE | ID: covidwho-1905892


Comorbidities such as hypertension could exacerbate symptoms of coronaviral disease 2019 (COVID)-19 infection. Patients with hypertension may receive both anti-COVID-19 and antihypertension therapies when infected with COVID-19. However, it is not clear how different classes of anti-hypertension drugs impact the outcome of COVID-19 treatment. Herein, we explore the association between the inpatient use of different classes of anti-hypertension drugs and mortality among patients with hypertension hospitalized with COVID-19. We totally collected data from 278 patients with hypertension diagnosed with COVID-19 admitted to hospitals in Wuhan from February 1 to April 1, 2020. A retrospective study was conducted and single-cell RNA-sequencing (RNA-Seq) analysis of treatment-related genes was performed. The results showed that Angiotensin II receptor blocker (ARB) and calcium channel blocker (CCB) drugs significantly increased the survival rate but the use of angiotensin-converting enzyme inhibitor/ß-block/diuretic drugs did not affect the mortality caused by COVID-19. Based on the analysis of four public data sets of single-cell RNA-Seq on COVID-19 patients, we concluded that JUN, LST1 genes may play a role in the effect of ARB on COVID-19-related mortality, whereas CALM1 gene may contribute to the effect of CCB on COVID-19-related mortality. Our results provide guidance on the selection of antihypertension drugs for hypertensive patients infected with COVID-19.

COVID-19 , Hypertension , Angiotensin Receptor Antagonists/therapeutic use , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Antihypertensive Agents/therapeutic use , COVID-19/complications , Calcium Channel Blockers/therapeutic use , Computational Biology , Humans , Hypertension/complications , Hypertension/drug therapy , Retrospective Studies , SARS-CoV-2
J Infect Dev Ctries ; 15(2): 230-236, 2021 03 07.
Article in English | MEDLINE | ID: covidwho-1125225


INTRODUCTION: The spatiotemporal patterns of Corona Virus Disease 2019 (COVID-19) is detected in the United States, which shows temperature difference (TD) with cumulative hysteresis effect significantly changes the daily new confirmed cases after eliminating the interference of population density. METHODOLOGY: The nonlinear feature of updated cases is captured through Generalized Additive Mixed Model (GAMM) with threshold points; Exposure-response curve suggests that daily confirmed cases is changed at the different stages of TD according to the threshold points of piecewise function, which traces out the rule of updated cases under different meteorological condition. RESULTS: Our results show that the confirmed cases decreased by 0.390% (95% CI: -0.478 ~ -0.302) for increasing each one degree of TD if TD is less than 11.5°C; It will increase by 0.302% (95% CI: 0.215 ~ 0.388) for every 1°C increase in the TD (lag0-4) at the interval [11.5, 16]; Meanwhile the number of newly confirmed COVID-19 cases will increase by 0.321% (95% CI: 0.142 ~ 0.499) for every 1°C increase in the TD (lag0-4) when the TD (lag0-4) is over 16°C, and the most fluctuation occurred on Sunday. The results of the sensitivity analysis confirmed our model robust. CONCLUSIONS: In US, this interval effect of TD reminds us that it is urgent to control the spread and infection of COVID-19 when TD becomes greater in autumn and the ongoing winter.

COVID-19/epidemiology , Nonlinear Dynamics , Atmospheric Pressure , Humans , Humidity , Meteorological Concepts , Population Density , Rain , Spatio-Temporal Analysis , Temperature , United States/epidemiology , Wind